The Business Of Biotech Podcast
-
First AI Antibody In Humans with Aulos' Aron Knickerbocker
7/14/2024
Data drives decision-making at Aulos Bioscience. It's also driven the career trajectory of its CEO. On this week's episode of the Business of Biotech podcast, we get an introspective walk through Aron Knickerbocker's strategically-orchestrated career path, from his early days in the labs at Bristol-Myers Squibb and Genentech to his leadership of Aulos Bioscience, a company that boasts the first AI-generated antibody in human clinical trials.
-
Drug Delivery Differentiators with Syncromune's Eamonn Hobbs
7/7/2024
Syncromune's Sync-T solid tumor therapeutic platform is, in a word, complex. The company's three phase 1 programs combine T-cell science with a proprietary drug delivery device to target solid tumors, specifically metastatic breast, non-small-cell lung, and castrate-resistant prostate cancers. But, while orchestrating a successful drug/device combination therapy presents unique regulatory challenges and requires a diverse array of in-house skillsets, President and CEO Eamonn Hobbs is confident. Why? He's done it before.
-
Topical Ocular Biologics with Claris Bio's Clarke Atwell
6/30/2024
Built on the back of hepatocyte growth factor discoveries by Harvard Drs. Reza Dana and Sunil Chauhan, Claris Bio is rewriting the ophthalmology rulebook. CEO Clarke Atwell acknowledges that it's not the first to bring topically-administered biologic therapies to the front of the eye, but if successful in the clinic, its Neurotrophic Keratitis candidate will vastly improve the patient experience. Atwell joins this episode of the Business of Biotech. Listen now!
-
C&G Regulatory Guidance with Lineage Cell Therapeutics' Brian Culley
6/23/2024
When we last caught up with Brian Culley, CEO of Lineage Cell Therapeutics, it was January 2021. A pandemic was raging. His company was moving mountains to keep its OpRegen dry AMD clinical trial together and did so despite lockdowns that kept a largely aged patient population from setting foot anywhere near a healthcare clinic. On his long-overdue return to the Business of Biotech, Culley opens up on how the company addressed struggling programs, wrestled manufacturing control issues and delivery inefficiencies in its spinal cord program to the ground, and maintained control of its regulatory progress along the way.
-
True DEI Value in Biopharma with Arcellx's Rami Elghandour
6/16/2024
Asked about his company’s rapid rise since taking the helm in 2021, Arcellx CEO Rami Elghandour cites a few critical and risky decisions, the execution of some specific people on his all-star team, and a relentless commitment to diversity, equity, and inclusion. Before you skepticize, let me assure you: the man brings receipts.
-
Mission-Driven Dementia Funding with DDF's Jonathan Behr
6/9/2024
If there's anyone qualified to analyze an early-stage therapeutic technology and place bets with other people's money, it's scientist-turned-venture capitalist Jonathan Behr, Ph.D. He built a distinguished venture capital career on the back of an MIT Ph.D. in biological engineering, having co-founded no fewer than 7 life sciences companies, served on or observed the boards of at least 17, and led investments at Pure Tech Ventures, the JDRF T1D Fund, SV Health investors, and now, the Dementia Discovery Fund, where he's a partner.
-
ADCs Ignited with Daiichi Sankyo Inc.'s Ken Keller
6/2/2024
Just a few years ago, Daiichi Sankyo wasn't considered a player in the oncology therapeutics space, and it certainly wasn't a player in ADCs. But then, just a few years ago, who was? Fast forward to 2023, and we see an ADC arena that drove nearly $100 billion in M&A, licensing, and partnership deals, and a Daiichi Sankyo that can rightfully lay claim to lighting that fire.
-
Accelerating ADCs with Mythic Therapeutics' Brian Fiske, Ph.D.
5/26/2024
Mythic Therapeutics Chief Scientific Officer and Co-Founder Brian Fiske, Ph.D. broke some unwritten protocol with his rapid and multifaceted transition from academia to industry. He calls his many, and sometimes concurrent, early experiences as an MIT Ph.D. student, a Flagship Ventures Fellow, a Bain consultant, a hospital researcher, and a biopharma consultant indicative of a young man who didn't want to make decisions.
-
The Anti-CDMO with CTMC's Jason Bock, Ph.D. and KSQ's Thomas Leitch
5/19/2024
This isn't your typical drug sponsor + CDMO story. In fact, CTMC's Jason Bock, Ph.D. says you shouldn't even classify his company as a CDMO. He's not wrong.
-
A New Prescription For PBMs with Allan Shaw
5/12/2024
Back by popular demand, biopharma industry opinionator extraordinaire Allan Shaw rejoins the Business of Biotech to expose the murky role Pharmacy Benefit Managers (PBMs) play in the last, costly mile of the drug distribution supply chain. Allan pulls no punches in his criticism of the current rebate structure and shares why the model leaves patients and manufacturers stuck with the spiraling tab.